

*Annual Review of Biochemistry*The Proteins of mRNA
Modification: Writers,
Readers, and ErasersMathieu N. Flamand,¹ Matthew Tegowski,¹
and Kate D. Meyer^{1,2}¹Department of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA; email: kate.meyer@duke.edu²Department of Neurobiology, Duke University School of Medicine, Durham, North Carolina, USAANNUAL
REVIEWS **CONNECT**www.annualreviews.org

- Download figures
- Navigate cited references
- Keyword search
- Explore related articles
- Share via email or social media

Annu. Rev. Biochem. 2023. 92:145–73

First published as a Review in Advance on
April 17, 2023The *Annual Review of Biochemistry* is online at
biochem.annualreviews.org<https://doi.org/10.1146/annurev-biochem-052521-035330>

Copyright © 2023 by the author(s). This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See credit lines of images or other third-party material in this article for license information.

**Keywords**epitranscriptome, RNA modifications, m⁶A, reader protein, methyltransferase, demethylase**Abstract**

Over the past decade, mRNA modifications have emerged as important regulators of gene expression control in cells. Fueled in large part by the development of tools for detecting RNA modifications transcriptome wide, researchers have uncovered a diverse epitranscriptome that serves as an additional layer of gene regulation beyond simple RNA sequence. Here, we review the proteins that write, read, and erase these marks, with a particular focus on the most abundant internal modification, N⁶-methyladenosine (m⁶A). We first describe the discovery of the key enzymes that deposit and remove m⁶A and other modifications and discuss how our understanding of these proteins has shaped our views of modification dynamics. We then review current models for the function of m⁶A reader proteins and how our knowledge of these proteins has evolved. Finally, we highlight important future directions for the field and discuss key questions that remain unanswered.

Contents

1. INTRODUCTION	146
2. WRITERS OF mRNA MODIFICATIONS	147
2.1. The <i>N</i> ⁶ -Methyladenosine Methyltransferase Complex: Discovery of the Core METTL3/METTL14 Dimer	147
2.2. Additional Methyltransferase Complex Components	148
2.3. <i>N</i> ⁶ -Methyladenosine Methylation Specificity	149
2.4. METTL16: An <i>N</i> ⁶ -Methyladenosine Methyltransferase with Key Roles in Cellular Metabolism	150
2.5. Writers of Other mRNA Modifications	150
3. <i>N</i> ⁶ -METHYLADENOSINE READER PROTEINS	152
3.1. YTH Domain-Containing Proteins	153
3.2. <i>N</i> ⁶ -Methyladenosine Recognition by the YTH Domain	153
3.3. Functions of YTH Domain-Containing Proteins	154
3.4. Other Direct <i>N</i> ⁶ -Methyladenosine-Binding Proteins	158
3.5. Indirect Readers	158
3.6. Readers of Other Modifications	159
4. ERASER PROTEINS	159
4.1. FTO	159
4.2. ALKBH5	162
4.3. Erasers of Other Modifications	163
5. CONCLUDING REMARKS	163

1. INTRODUCTION

Cellular RNAs contain over 150 different chemical modifications, most of which reside in noncoding RNAs such as rRNA and tRNA. While the presence of modifications in these abundant RNA species has been known for decades, much of our understanding of post-transcriptional modifications in mRNAs has emerged within just the past several years. These studies have been fueled by new technologies that have enabled the detection and quantification of mRNA modifications and the precise mapping of modification sites transcriptome wide. These efforts have revealed a growing epitranscriptome composed of diverse modifications of varying abundance.

Chemical modifications to mRNAs were initially discovered in the 1970s, when researchers identified *N*⁶-methyladenosine (*m*⁶A) and *N*⁵-methylcytidine (*m*⁵C) from bulk hydrolyzed nucleosides isolated from oligo(dT)-purified cellular RNA (1, 2). This work revealed *m*⁶A to be the most abundant internal modification, and subsequent studies determined that it was present in a GAC or AAC consensus sequence (3, 4). However, due to a lack of methods for profiling *m*⁶A transcriptome wide, it was several decades before individual methylated mRNAs throughout the transcriptome would be discovered. Then, in 2012, the development of antibody-based approaches (methylated RNA immunoprecipitation sequencing and *m*⁶A sequencing) for global *m*⁶A detection revealed thousands of methylated mRNAs and identified a distinct distribution of *m*⁶A within long internal exons and near the 5' end of terminal exons (5, 6). These studies, in addition to the discovery that *m*⁶A could be reversibly modified through the action of demethylating enzymes (7), sparked a renewed interest in mRNA modifications.

In this review, we provide an overview of the writers, readers, and erasers of mRNA modifications, with a primary focus on *m*⁶A. We review the recent advances in our understanding of




Figure 1

Regulation and function of m^6A writer proteins. (a) m^6A is deposited co-transcriptionally by a methyltransferase complex that includes METTL3 as the catalytic subunit and additional proteins METTL14, WTAP, RBM15/15B, VIRMA, HAKAI, and ZC3H13. This complex is recruited to RNAs through interactions with H3K36me3 histone marks, transcription factors, and RNA pol II, and its activity can be influenced by transcription rate. METTL3 deposits m^6A within the DRACH consensus sequence, which is where the majority of m^6A sites within mRNAs reside. (b) In the cytoplasm, METTL3 and METTL16 interact with the translation initiation machinery to promote mRNA translation independently of their methyltransferase activity. (c) A subset of mRNAs can be methylated by METTL16, which requires distinct sequence and structural elements. METTL16 also deposits m^6A in snRNAs and lncRNAs. At the mRNA 5' end, PCIF1 deposits m^6A_m adjacent to the cap. Abbreviations: eIF, eukaryotic initiation factor; K36, H3K36 trimethylation; lncRNA, long noncoding RNA; m^6A , N^6 -methyladenosine; m^6A_m , $N^6,2'$ - O -dimethyladenosine; m^7G , N^7 -methylguanosine; METTL, methyltransferase-like; RNA pol II, RNA polymerase II; SAH, S -adenosyl-homocysteine; SAM, S -adenosyl-methionine; snRNA, small nuclear RNA; WTAP, Wilms' tumor 1-associated protein.

how these proteins are regulated and their impact on gene expression and cellular function, and we highlight links to human disease. We also discuss key findings as well as controversies and describe emerging areas of importance.

2. WRITERS OF mRNA MODIFICATIONS

2.1. The N^6 -Methyladenosine Methyltransferase Complex: Discovery of the Core METTL3/METTL14 Dimer

m^6A is deposited co-transcriptionally by a large methyltransferase complex (MTC) (Figure 1a). Efforts to identify the factors responsible for m^6A formation began in the early 1990s, when researchers demonstrated that nuclear extracts from HeLa cells were capable of methylating substrate RNAs in vitro (8). A large complex was subsequently purified from HeLa cell nuclear extracts that had multiple components that were required for methyltransferase activity (9, 10). Within this complex, a 70-kDa protein with S -adenosyl-methionine (SAM)-binding activity was identified and subsequently cloned from HeLa cell cDNA (9). This protein, MT-A70 (10), was found to be

catalytically active in vitro, expressed in many tissues, and predominantly localized to the nucleus (9).

MT-A70 belongs to the methyltransferase-like (METTL) superfamily of proteins with SAM-binding domains and is now known as METTL3. METTL14, another member of this family with homology to METTL3, has since been demonstrated to be a critical component of the MTC. Initial studies indicated that METTL14 had methyltransferase activity in vitro (11). However, later work showed that this activity was due to copurification of METTL3, which forms a strong dimer with METTL14 (12). Structural studies further confirmed that only METTL3 binds to SAM, while METTL14 contributes to substrate recognition and stabilizes the interaction between METTL3 and RNA (12–14) (**Figure 1a**). Thus, although METTL14 does not have methyltransferase activity, it is required for target RNA methylation. Indeed, multiple studies have shown that depletion of either METTL3 or METTL14 alone results in a strong decrease in the abundance of m⁶A methylation in cellular mRNAs (11, 15).

In addition to its m⁶A methyltransferase activity, METTL3 has also been shown to have methyltransferase-independent functions. In cancer cells, METTL3 promotes the translation of a subset of mRNAs by binding to the 3' untranslated region (UTR) and mediating interactions with eIF3h through mRNA looping (16, 17) (**Figure 1b**). Through this mechanism, METTL3 enhances the translation of oncogenic transcripts including *EGFR*, *TAZ*, and *BRD4* and promotes cellular transformation and tumor growth (16, 17).

2.2. Additional Methyltransferase Complex Components

In 2008, FIP37 was identified in a yeast two-hybrid screen for interactors of MTA, the m⁶A methyltransferase in *Arabidopsis thaliana* (18). Subsequent studies showed that the yeast homolog of FIP37, MUM2, also interacts with the yeast m⁶A methyltransferase IME4 and contributes to m⁶A deposition (19). *FIP37/MUM2* are homologs of mammalian Wilms' tumor 1-associated protein (*WTAP*), which in 2014 was shown to bind in complex with METTL3 and METTL14 and to be indispensable for MTC-mediated m⁶A methylation in mRNAs (11, 15, 20). *WTAP* regulates the localization of the MTC by recruiting it to nuclear speckles, sites of high transcriptional activity (11, 15, 20) (**Figure 1a**).

The discovery of other MTC components was facilitated by proteomics studies that sought to identify interacting partners of METTL3, METTL14, and *WTAP* (15, 21, 22). These studies identified KIAA1429, also known as *VIRMA*, as an interacting partner of *WTAP*. This was consistent with previous work showing a similar interaction in *Drosophila* (23). Biochemical studies further demonstrated that depletion of *VIRMA* leads to a significant decrease in m⁶A in poly(A) RNA, indicating its importance for a functional MTC (21). In addition to *VIRMA*, Horiuchi and colleagues (22) identified *RBM15* as a *WTAP* interactor. Later, it was confirmed that *RBM15* and its paralog *RBM15B* interact with the MTC in a *WTAP*-dependent manner (24). Depletion of *RBM15/15B* results in a substantial loss of m⁶A in poly(A) RNA and in the long noncoding RNA (lncRNA) *XIST*, confirming a functional role for *RBM15/15B* in the methylation of cellular RNAs. Identification of *RBM15/15B*-binding sites using individual-nucleotide resolution cross-linking and immunoprecipitation (CLIP) revealed that these proteins bind U-rich regions near methylated, but not unmethylated, DRACH motifs (D = A,G,U; R = A,G; H = A,C,U), which are preferred consensus motifs where m⁶A methylation occurs (24). This suggests that *RBM15/15B* may help target the MTC to a subset of sites near U-rich sequences (**Figure 1a**).

HAKAI, an E3 ubiquitin ligase, was also identified within the MTC in proteomics studies (22). Not only has this association been confirmed for the *HAKAI* homologs in *Arabidopsis* and *Drosophila* but depletion of the *HAKAI* homolog in each species leads to a reduction of m⁶A

in mRNA (25–27), demonstrating an evolutionarily conserved role in methylation. Interestingly, although HAKAI is an E3 ubiquitin ligase, its catalytic activity is not required for its role in regulating adenosine methylation in flies (26), suggesting that it most likely does not regulate MTC activity by ubiquitination. Indeed, in contrast to its described role as an E3 ligase, Hakai has been shown to stabilize the homologs of core MTC components METTL3, METTL14, and WTAP in flies (26).

The zinc finger protein ZC3H13 is an additional MTC component that was identified using immunoprecipitation and mass spectrometry (21). Knockdown of ZC3H13 leads to reduced m⁶A deposition and, like other MTC components, it is critical for mouse embryonic stem cell (mESC) self-renewal (21, 28). Mechanistically, ZC3H13 regulates the MTC by promoting the nuclear localization of WTAP, VIRMA, and HAKAI (28).

2.3. N⁶-Methyladenosine Methylation Specificity

Early biochemical studies using enzymatic digestion of radiolabeled cellular RNA indicated that m⁶A occurs within a GAC or AAC consensus sequence (3, 4). More recent transcriptome-wide m⁶A mapping studies have further identified the preferred extended DRACH motif (5, 6). However, only a small proportion of DRACH motifs contain m⁶A, suggesting that other factors contribute to methylation specificity. Methylation of specific residues may be primarily guided by cis elements within the RNA, giving rise to a hard-wired m⁶A code that is dictated primarily by sequence and, to a lesser extent, RNA structure (29). Additionally, gene architecture appears to contribute to m⁶A distribution, as m⁶A is depleted near exon junctions but enriched within long internal exons and in the beginning of terminal exons, the latter giving rise to the appearance of stop-codon-proximal enrichment, which is a characteristic feature of m⁶A across diverse cell types and species (5, 6, 30–33). The relative depletion of m⁶A near exon junctions is likely due to occlusion of DRACH motifs by the exon junction complex (EJC). Evidence for this comes from recent studies showing that depletion of EJC components increases methylation of regions near splice junctions (31–33). This recently discovered role for the EJC in shaping m⁶A distribution is an important advance in our understanding of how m⁶A methylation specificity is achieved.

Crosstalk between the MTC and chromatin marks may also add to m⁶A specificity. Studies in mESCs have shown that the MTC is recruited through METTL14 to the H3K36 trimethylation mark (H3K36me3), which is enriched at genomic regions near m⁶A (34) (**Figure 1a**). Depletion of the H3K36 methyltransferase SETD2 leads to reduced m⁶A at approximately 46% of co-regulated H3K36me3/m⁶A sites, indicating that this may be a mechanism for guiding the MTC to a substantial proportion of RNAs destined for methylation but also suggesting that other factors exist (34). Indeed, several transcription factors, including SMAD2/3, CEBPZ, and p53, have been shown to bind and recruit the MTC to methylate specific target RNAs (35–37) (**Figure 1a**). In addition, RNA polymerase II (RNA pol II) transcription rate affects methylation frequency, with slower transcription resulting in more methylation and decreased mRNA stability (38) (**Figure 1a**). This is reminiscent of other co-transcriptional processes like splicing and 3' end formation that are also altered by transcription rate (39).

In general, m⁶A patterns are relatively static across tissues and even species (40), but there are transcripts that exhibit distinct tissue- and cell-type-specific methylation profiles, even when accounting for differences in gene expression (40, 41). Variability in the expression of specific transcription factors or abundance of H3K36me3 may explain some of this variability. Studies using single-cell m⁶A profiling have shown that many more consensus motifs are methylated in mRNAs than previously thought based on m⁶A mapping in bulk cells (42). Most of these sites occur rarely throughout a population of cells, but some RNAs contain high-frequency sites that are

methylated in nearly all cells. Thus, chromatin marks and transcription-associated proteins may help recruit the MTC to sites of nascent transcription to facilitate methylation at any suitable motif in the region, but in some cases, there may be other unknown factors that contribute to consistent methylation at the same adenosines in all cells.

Posttranslational modifications (PTMs) to MTC components are additional factors that may control methylation. For instance, several lysine residues within METTL3 are susceptible to SUMOylation, which represses its methyltransferase activity (43). Additionally, methylation of arginine residues within the C terminus of METTL14 promotes its interactions with RNA and RNA pol II, leading to enhanced m⁶A methylation (44). Posttranslational modification of the MTC machinery remains a relatively underexplored area, so future studies are needed to better understand how modification of MTC components controls m⁶A deposition.

2.4. METTL16: An N⁶-Methyladenosine Methyltransferase with Key Roles in Cellular Metabolism

Although METTL3 is responsible for methylating the majority of cellular mRNAs, a small number of sites are targeted for methylation by METTL16. In addition to depositing m⁶A in the U6 small nuclear RNA (snRNA) (45, 46) and the lncRNAs *MALAT1* and *XIST* (46, 47), METTL16 also methylates the *MAT2A* mRNA, which encodes the SAM synthetase, as part of a feedback mechanism that helps maintain cellular SAM levels (**Figure 1c**). When SAM levels are high, METTL16 methylates a conserved hairpin in the *MAT2A* 3' UTR, leading to intron retention, which blocks the production of a functional protein. Depletion of SAM leads to reduced enzymatic turnover of METTL16 and increased occupancy on the *MAT2A* transcript, which in turn promotes *MAT2A* splicing and increased MAT2A protein production (45). In *Caenorhabditis elegans*, the METTL16 homolog METT-10 also regulates SAM levels by methylating the SAM synthetase mRNA to regulate its splicing (48, 49). However, the mechanism differs from mammalian cells and involves direct inhibition of the U2AF35 splicing factor by 3' splice site m⁶A (48, 49). Nevertheless, this suggests an evolutionarily conserved role for METTL16 as a regulator of SAM homeostasis.

Although both METTL3 and METTL16 use SAM as a methyl donor (**Figures 1a,c**), they recognize target RNAs through different mechanisms. While METTL3 targets DRACH motifs, METTL16 methylates adenosines within a distinct sequence motif (UACAGAGAA) that resides within a hairpin structural element (46–48). Depletion of METTL16 causes a significant reduction of total m⁶A levels in poly(A) RNA and loss of m⁶A in thousands of mRNAs (45, 50). However, due to its role in regulating SAM levels, it is difficult to uncouple METTL16-mediated methylation from changes due to reduced METTL3 activity, and METTL16 is likely to methylate only a few hundred mRNAs or fewer (50). This is consistent with the fact that the vast majority of m⁶A sites in mRNAs exist within the DRACH motif (3–6). Interestingly, like METTL3, METTL16 has also been shown to have methyltransferase-independent functions by promoting translation initiation (50) (**Figure 1b**). METTL16 is predominantly localized to the cytoplasm; therefore, while it clearly directs the nuclear methylation of a subset of cellular RNAs, a major function of METTL16 may be to control gene expression through translation regulation.

2.5. Writers of Other mRNA Modifications

Pseudouridine (ψ) is a frequent internal mRNA modification, representing 0.3–0.4% of uridines in mammalian cells (51). ψ profiling studies have identified several hundred to several thousand ψ sites in human and yeast mRNAs (51–54). Several pseudouridine synthase (PUS) enzymes have been shown to catalyze ψ formation in mRNAs, but PUS1 and PUS7 are predominant




Figure 2

Writers, readers, and erasers of other mRNA modifications. Shown are the major regulatory proteins of ψ , m¹A, m⁵C, ac⁴C, and N_m as well as the types of RNAs in which these modifications have been identified. Further characterization of many of these regulatory proteins will be important for understanding how these modifications are controlled in cells and their contribution to gene expression. In some cases, eraser and reader proteins have not yet been identified. TBL3 (marked with an asterisk) has been identified as an *in vitro* reader. Abbreviations: ψ , pseudouridine; ac⁴C, N⁴-acetylcytidine; ALKBH, AlkB homolog; FBL, fibrillarin; FTO, fat mass and obesity-associated; HPRT, hypoxanthine phosphoribosyltransferase; HRSP, heat-responsive protein; m¹A, N¹-methyladenosine; m⁵C, N⁵-methylcytidine; m⁷G, N⁷-methylguanosine; MetRS, methionine aminoacyl tRNA^{Met} synthetase; NAT10, nuclear acetyltransferase 10; N_m, methylation of the 2'-hydroxyl of the ribose backbone; NSUN, NOP2/Sun domain family; PUS, pseudouridine synthase; snRNA, small nuclear RNA; TBL, Transducin beta-like; TET, ten-eleven translocation; TRMT, tRNA methyltransferase; YBX1, Y box binding protein.

PUSs common to both mammals and yeast (52–54) (**Figure 2**). Loss of these enzymes leads to alterations in splicing and 3'-end processing, suggesting a role in regulating co-transcriptional mRNA processing (54). Additionally, pseudouridylation of stop codon uridines can promote translational readthrough, providing a potential mechanism for premature stop codons to bypass nonsense-mediated decay (55).

In contrast to ψ and m⁶A, some of the additional internal mRNA modifications that have been identified are less abundant. N¹-methyladenosine (m¹A) is deposited in mammalian tRNAs by a dimer of TRMT61A and TRMT6 (56) (**Figure 2**). While there is evidence that this complex can add m¹A to mammalian mRNAs (57), the extent to which mRNAs contain m¹A remains an active area of research. Some studies have reported hundreds or thousands of sites, while others suggest that m¹A is present at only a small number of residues, including in mitochondrial mRNAs, and mostly at low stoichiometry (57–60). Similarly, N⁴-acetylcytidine (ac⁴C) is present in human rRNA and tRNAs, but reports of its abundance in mRNAs have been variable, with mass spectrometry estimates varying by an order of magnitude. NAT10 has been identified as the ac⁴C

acetyltransferase (**Figure 2**), and a recent study using a chemical reduction approach to map ac⁴C transcriptome wide identified over 7,000 sites, most of which were eliminated in *NAT10* knock-out cells (61–63). Interestingly, most of these sites are found in the 5' UTR and are associated with increased translation initiation (61). Further studies examining the distribution of ac⁴C and m¹A and whether they differ across cell types or cellular conditions are important. Additionally, although challenging, measures of stoichiometry for these and for all modifications will be critical for a better understanding of their impact on cellular RNAs.

Like m⁶A, the m⁵C modification was first observed in the 1970s in biochemical studies of polyadenylated RNA (64). This was reported in RNA from cultured hamster cells but not in other mammalian cell lines (1, 3). In 2012, a bisulfite sequencing approach reported widespread m⁵C in mammalian mRNAs (65). However, subsequent studies have found more variable numbers of sites, and mass spectrometry data show that m⁵C is much less abundant than prevalent modifications like m⁶A (66–69). NSUN2 has been identified as the primary m⁵C methyltransferase in mammalian mRNAs (65, 70) (**Figure 2**). Importantly, NSUN2 is upregulated in many cancers, and mutations in NSUN2 can result in intellectual disability, although some of the underlying mechanisms likely relate to its tRNA methyltransferase activity (71, 72).

In addition to base modifications, methylation of the 2'-hydroxyl of the ribose backbone (N_m) is prevalent in tRNAs, rRNAs, and small nuclear RNAs (73). N_m is a low-abundance modification in mRNAs, and knowledge of specific transcripts that contain N_m has been limited by difficulties in detecting this mark transcriptome wide. Dai and colleagues (74) reported nearly 700 N_m sites in HEK293 cells and over 2,100 sites in HeLa cells; however, roles for N_m in mRNA regulation and its abundance in other cell types remain poorly understood. N_m in rRNAs is deposited by the methyltransferase fibrillarin (FBL) (75) (**Figure 2**), and a recent study demonstrated that FBL can also install N_m in the peroxidasin mRNA (76). This results in increased mRNA abundance but decreased translation efficiency, demonstrating a functional consequence of internal N_m within this transcript.

In addition to internal N_m, the first transcribed nucleotide adjacent to the 5' cap is also 2'-*O*-methylated by CMTR1 in mammalian cells (77, 78). 20–30% of these are adenosine residues that are additionally methylated at the N⁶ position by PCIF1 to form N⁶,2'-*O*-dimethyladenosine (m⁶A_m) (79–81) (**Figure 1a**). Recent mapping studies in mammalian cells have found between 800 and 3,000 m⁶A_m-containing mRNAs (80–82), with possible differences between cell types (40, 81). Some studies have indicated increased stability of m⁶A_m-containing mRNAs (80, 82, 83), possibly due to inhibition of 5' decapping (83). m⁶A_m may also play roles in translation, with some studies reporting a modest increase in translation of m⁶A_m-containing mRNAs (82, 83). However, other studies have found no change in translation efficiency upon PCIF1 depletion (80). Expression of a reporter mRNA with A_m or m⁶A_m at the 5' end in PCIF1-knockout cells showed decreased translation of the m⁶A_m-containing transcript compared to A_m mRNA (81). These discrepancies may indicate biological context-dependent effects of m⁶A_m, since different cell lines were used across studies. This is supported by evidence that m⁶A_m:A_m ratios can vary widely across tissues in mice (e.g., 15:1 in brain, 2:1 in liver) (84). However, this needs to be further explored to better understand the functions of m⁶A_m.

3. N⁶-METHYLADENOSINE READER PROTEINS

m⁶A exerts many of its biological functions through the regulation of RNA–protein interactions, including the recruitment of m⁶A reader proteins. Reader proteins can either directly recognize m⁶A or bind indirectly to RNAs through m⁶A-mediated structural changes. In the past decade, several studies have employed biochemical assays to identify and characterize m⁶A reader proteins. Although these proteins can recognize methylated RNAs through a variety of RNA-binding

domains (RBDs), the most robust and specific interaction with m⁶A is mediated through the YT521-B homology (YTH) domain.

3.1. YTH Domain-Containing Proteins

The first m⁶A reader proteins were identified with RNA pulldown assays using methylated and unmethylated RNA baits followed by mass spectrometry (6). This revealed two members of the YTH domain-containing family of proteins: YTHDF2 and YTHDF3, as well as the RNA-binding protein (RBP) ELAVL1 (also known as HUR), as proteins with enhanced binding to m⁶A.

The YTH domain was first identified in the splicing factor YT521-B (now known as YTHDC1) as a novel RBD (85, 86). Homologous YTH domain-containing proteins have been identified in diverse organisms, from yeast and plants to mammals, suggesting important functions throughout evolution. Interestingly, while the *Saccharomyces cerevisiae* YTHDF homolog MRB1 binds to m⁶A, the *Schizosaccharomyces pombe* YTH domain protein Mmi1 does not, and the presence of m⁶A actually reduces its affinity for RNA (87, 88). In mammals, there are five YTH domain-containing proteins: YTHDF1, 2, and 3 (also called DF1, DF2, and DF3); YTHDC1 (DC1); and YTHDC2 (DC2). All share the highly conserved YTH domain and are capable of binding m⁶A, although studies suggest that YTHDC2 exhibits lower specificity for m⁶A and may bind nonmethylated regions (discussed in Section 3.3.2.). The YTH proteins also differ in size, domain organization, and subcellular localization: While the DF proteins are predominantly cytoplasmic with shared domain architectures, DC1 is nuclear, and DC2 exhibits a nucleocytoplasmic localization with several distinct domains not found in the other YTH proteins (**Figure 3a**).



3.2. N⁶-Methyladenosine Recognition by the YTH Domain

The YTH domain is a highly conserved domain of approximately 130 residues that adopts an open α/β fold containing six β -sheets surrounded by α -helices (89–93). The methylated adenosine is lodged in an aromatic cage consisting of three tryptophans (DF1, DF2, DF3) or two tryptophans and a leucine residue (DC1, DC2). The N⁶-methyl moiety is nested within a hydrophobic pocket and faces the tryptophan residue forming the base of the cage, and interactions with the adenine base are stabilized by hydrogen bonds between the nucleobase and the sidechains and backbones of neighboring residues (89, 91–93) (**Figure 3b**).

The reported binding affinities of the YTH domain for methylated RNA are relatively low, with in vitro measurements generally ranging from 100 nM to 3 μ M for the DFs and DC1, and a \sim 5–25-fold lower affinity has been reported for DC2 (91–95). However, the YTH domain has a 10–100-fold higher affinity for m⁶A versus unmodified A (90, 93, 96). Additionally, the YTH domain can recognize m⁶A relatively indiscriminately, as mutation of m⁶A-adjacent nucleotides at positions –2, –1 and +1 does not significantly alter binding of the YTH domain in vitro (91, 94). An exception is the YTH domain of DC1, which shows a slight preference for G at the –1 position (91, 93, 94). One limitation to in vitro binding assays is that they often use RNAs of fixed length and sequence, and the binding conditions may not mimic the environment of the cell. Methylated RNA may need to be in a favorable conformation to enable m⁶A recognition by the YTH domain. For example, DF2 preferentially binds to m⁶A in single-stranded regions or when flanked by a 5' bulge when in a duplex (96). In contrast, when m⁶A is in a Watson–Crick conformation, it remains inaccessible for recognition by the YTH domain. Significantly, 11–30% of all m⁶A sites are predicted to be in regions inaccessible for binding (96). Similarly, the accessibility of sites can also be impaired by binding of other RBPs. For example, the high stoichiometry m⁶A sites found in the 18S and 28S rRNAs are not bound by YTH domain proteins in CLIP sequencing studies, likely because they are buried within the ribosome (24).

3.3. Functions of YTH Domain-Containing Proteins

3.3.1. YTHDC1. DC1 was initially characterized as a spliceosome-interacting protein localized to nuclear speckles (97, 98), and it is unique among the YTH proteins in that it is exclusively nuclear. This localization is driven by a nuclear localization sequence as well as low-complexity regions that are required for DC1 condensation in nuclear speckles (Figure 3a) (98–100).



(Caption appears on following page)

Figure 3 (Figure appears on preceding page)

m⁶A reader proteins have diverse functions and mechanisms of m⁶A recognition. (a) Schematic showing the domain structures of direct m⁶A-binding proteins. YTHDF1/2/3, YTHDC1, and YTHDC2 recognize m⁶A through the highly conserved YTH domain. KH domains mediate m⁶A binding in FMRP and IGF2BP proteins. The KH domains required for m⁶A recognition are underlined. (b) Surface representation of the YTH domain of human YTHDF1 in complex with m⁶A (PDB ID: 4RCJ). m⁶A is nested in a hydrophobic pocket of the YTH domain. The three tryptophan residues forming the aromatic cage surrounding m⁶A are highlighted, as is the position of the methyl moiety in m⁶A. (c) m⁶A readers impact several aspects of RNA processing and function. In the nucleus, YTHDC1 regulates chromatin accessibility, promotes degradation of carRNAs, and binds to m⁶A sites within the lncRNA *XIST* to promote gene silencing. YTHDC1 also interacts with splicing factors and controls alternative splicing, polyadenylation, and nuclear export. FMRP recognition of methylated transcripts also promotes their export. In the cytoplasm, m⁶A is recognized by eIF3 to promote cap-independent translation of mRNAs with 5' UTR m⁶A sites. YTHDF proteins can localize to stress granules and P-bodies, and all three proteins can promote mRNA decay. The role of YTHDF2 in mRNA destabilization is the most extensively studied and can include recruitment of various effector proteins to promote decapping, deadenylation, or endonucleolytic decay. Binding of YTHDF1 and YTHDF3 can also lead to increased translation of methylated mRNAs in some cell types. Abbreviations: carRNA, chromatin-associated regulatory RNA; FMRP, fragile X mental retardation protein; HNRNPC, heterogeneous nuclear ribonucleoprotein C; KH, K homology; lncRNA, long noncoding RNA; m⁶A, N⁶-methyladenosine; m⁷G, N⁷-methylguanosine; NLS, nuclear localization signal; PDB ID, Protein Data Bank identifier; RNA pol II, RNA polymerase II; UTR, untranslated region; YTH, YT521-B homology.

Consistent with its nuclear localization, DC1 regulates several steps of pre-mRNA processing (Figure 3c). Studies in HeLa cells have shown that DC1 is bound competitively by the splicing proteins SRSF3 and SRSF10 to regulate exon inclusion (99) and nuclear export (101). In mouse oocytes, DC1 can interact with CPSF6, SRSF3, and SRSF7 to regulate splicing and alternative polyadenylation of m⁶A-modified mRNAs (102). DC1 was also found to promote the stability of RNA at sites of double-strand DNA breaks following recruitment and activation of METTL3 (103). Additionally, DC1 binds to the highly methylated lncRNA *XIST* and is essential to *XIST*-mediated gene silencing (24).

The functions of DC1 suggest that it binds to chromatin-associated RNAs rapidly after m⁶A deposition. For example, in mESCs, DC1 is required for maintenance of stemness and silencing of transposons through the recruitment of SETDB1 and H3K3me3 deposition (104), and in HEK293T cells, m⁶A and DC1 contribute to the removal of the repressive H3K9me2 marks through the recruitment of KDM3B (105). DC1 also contributes to transcription regulation by facilitating the degradation of m⁶A-containing chromatin-associated regulatory RNAs (carRNAs) and limiting their ability to promote open chromatin (106).

DC1 plays important roles in ESCs and is essential for embryonic development (102), so it will be important going forward to understand how DC1 activity is regulated. One possibility is that DC1 function is influenced by the activation of specific signaling pathways. For instance, DC1 contains multiple phosphorylation sites, and its localization to nuclear speckles can be influenced by activation of the Src family kinase FYN (98).

3.3.2. YTHDC2. DC2 exhibits a unique domain composition compared to the other YTH proteins. DC2 is the largest of the YTH proteins and contains several conserved protein domains in addition to its YTH domain, including ankyrin repeats, an oligonucleotide-binding fold, and DEAD-like helicase domains (Figure 3a). The cellular functions of DC2 are still being elucidated, but it has been shown to be important for spermatogenesis and oogenesis through its regulation of mRNA stability and translation (107–109). CLIP-based studies have revealed that DC2 has a unique binding pattern characterized by enrichment in introns and intergenic regions and within the coding sequence of mRNAs (24), which is distinct from the distribution of m⁶A and the binding sites of other YTH proteins. Additionally, DC2 binding sites show poor overlap with mapped m⁶A sites (24, 110), suggesting that DC2 may not function exclusively as an m⁶A reader. Indeed, DC2's YTH domain is dispensable for its biological function in spermatogenesis, and DC2 can

bind target RNAs in poly(U) sequences in the absence of its YTH domain (110, 111). Consistent with this, the binding affinity and specificity of DC2 toward m⁶A is much lower than for other YTH proteins (94). Further studies are necessary to determine the extent of m⁶A-dependent and m⁶A-independent RNA regulation by DC2.

3.3.3. YTHDF proteins. The DF proteins include three cytoplasmic proteins sharing 65–70% sequence identity and a similar global domain organization. The YTH domain is found near the C terminus and is preceded by a low-complexity region of ~350–400 residues that are P/Q/N rich (**Figure 3a**). Low-complexity regions are known to contribute to protein condensation and liquid–liquid phase separation (LLPS), and consistent with this, the low-complexity domain is required for LLPS of DF proteins (112) and mediates their association with stress granules (113) and P-bodies (114). Initially, it was proposed that DF proteins have distinct and partially overlapping functions: DF1 promotes translation of its target mRNAs (115), DF2 promotes their degradation (114), and DF3 promotes both functions (116). However, this model has recently been challenged by a unified model for DF protein function, which proposes that all three DF proteins act redundantly to promote mRNA decay with no effect on translation (95, 117, 118). Interestingly, single-molecule analysis of the RNA targets of DF proteins has revealed that individual mRNAs can be bound more than once by different DF proteins throughout their lifetime (119). This suggests that DF proteins may not immediately promote decay every time they bind to their target RNAs. The precise function of DF proteins has been examined in only a handful of cell types and experimental systems, and future experiments are necessary to understand the full extent of DF-mediated regulation.

3.3.4. mRNA decay. DF2 was initially implicated in m⁶A-mediated mRNA instability following the observation that the abundance of its target mRNAs was increased following DF2 depletion (114). DF2 was also found to traffic to P-bodies and contribute to mRNA deadenylation and decay (114) (**Figure 3c**). This effect is consistent with metabolic labeling studies performed in the 1970s, which suggested selective instability of m⁶A-containing mRNAs (120), as well as with the finding that *Mettl3* depletion leads to increased mRNA abundance (121, 122). Subsequent work identified a direct interaction between DF2 and the CNOT1 scaffolding subunit of the CCR4–NOT deadenylase complex (123). Interestingly, this study found no direct interaction between CNOT and either DF1 or DF3 and showed that tethering of DF1 or DF3 to a reporter mRNA caused deadenylation, but the magnitude was substantially reduced compared to tethering of DF2 (123). These results suggest that all three DF proteins can mediate mRNA degradation but that the effect is strongest for DF2. This is consistent with recent studies in mESCs and HeLa cells demonstrating that the loss of all three DF proteins causes a greater increase in methylated mRNA abundance compared to loss of any single DF protein alone and that depletion of DF2 has a more pronounced effect on mRNA stability compared to depletion of DF1 or DF3 (95, 117). This is also consistent with the finding that DF2-bound RNAs are less likely to be subsequently bound by other DF proteins compared to DF1- or DF3-bound RNAs, potentially because DF2 targets are more efficiently processed for decay (124).

In addition to recruitment of the CCR4–NOT deadenylase complex, DF2 can interact directly with HRSP12 to recruit RNase P/MRP and elicit endonucleolytic cleavage and degradation of target mRNAs (125) (**Figure 3c**). DF2 can also promote mRNA decapping through interactions with UPF1 and recruitment of PNRC2 and DCP1A (126). These interactions are not detected with DF1 or DF3, again suggesting that DF2 has a more prominent role in mRNA decay.

3.3.5. Translation control. A role for DF1 in promoting translation was initially demonstrated in ribosome profiling studies in HeLa cells, which showed that DF1 depletion leads to reduced

translation efficiency of its target mRNAs (115). DF1 was also shown to interact with eIF3a/b and eEF2 to promote translation initiation and elongation of methylated mRNAs (115, 127). However, other studies have failed to observe global effects on translation following loss of DF1 and suggest a more limited role for m⁶A and DF proteins in translational control (95, 112, 117, 128). It is likely that the translation-promoting function of DF1 is influenced by cell type or cellular conditions. For instance, several studies support a role for DF1 in promoting translation in neurons (129–131), and the positive effect of DF1 tethering on translation is most evident during stress recovery (115). In addition to DF1, DF3 has been reported to promote translation of its target mRNAs, but it appears to do so in cooperation with DF1 (116, 132). Future studies examining cell-type- and context-dependent effects of DF1/DF3-mediated translation regulation and the mechanisms of their cooperative function are important for a more complete understanding of how DF proteins impact protein production.

3.3.6. Biological context. Many studies of DF proteins have been performed in immortalized cells at steady state. It is therefore important to consider how factors like expression level, local subcellular concentration, and cell-type-specific interactions may differentially influence DF proteins when proposing general models for their function. For instance, studies in the nervous system have shown that perturbation of distinct DF proteins results in drastically different phenotypes (133). In the developing brain, DF2 is essential for neuronal progenitor cell differentiation and methylated mRNA clearance (134). In contrast, DF1 is important for axonal guidance (135), and in mature neurons, it is required for learning and memory through translational control of its target RNAs (129). Moreover, DF1 and DF3, but not DF2, are required for proper synapse morphology (130). Additionally, DF2 and DF3, but not DF1, contribute to the localization of the methylated mRNAs *Camk2a* and *Map2* to neurites in hippocampal neurons (124). Furthermore, depletion of *Mett13* or *Mettl14* in mature neurons does not lead to a global increase in m⁶A-modified mRNAs, suggesting that mRNA decay is not the primary function of m⁶A in neurons (124, 136, 137). This is an important distinction from the effects of m⁶A observed in studies in mESCs and other dividing cells and suggests that DF protein function depends on context-dependent factors.

How could DF proteins mediate these differential effects? Analysis of proximity labeling data sets in HeLa cells suggests that DF1, DF2, and DF3 interact with a similar set of proteins (95). In contrast, other studies have reported unique protein interacting partners with the different DF proteins (125, 126, 138). The low-complexity region is where most differences occur among the DFs, and it is important for these unique interactions (125, 126, 138). It is therefore possible that while many DF-binding partners are conserved among the three proteins, subtle differences in DF protein sequence can enable unique interactions that then promote distinct functions in certain contexts.

It is also possible that PTMs of DF proteins enable selective regulation of these otherwise highly similar proteins. All three DF proteins contain several phosphorylation sites within their low complexity regions (139). Phosphorylation of these regions could prevent protein condensation in RNA granules and could be an important mechanism to control their activity in response to stress or cellular stimuli. Other modifications have also been described in DF proteins. For example, DF2 is ubiquitinated in a cell-cycle dependent manner, which influences its stability (140). Additionally, stress-dependent SUMOylation of the DF2 C terminus was found to increase its affinity toward m⁶A-modified mRNAs (141). Interestingly, the DF2 SUMOylation sites that have been reported are not found in DF1 and DF3. Going forward, it will be important to understand which PTMs are found in the various DF proteins and whether they are differentially regulated in a cell-type- or context-specific manner.

3.4. Other Direct N^6 -Methyladenosine-Binding Proteins

In addition to the YTH-domain-containing proteins, several other RNA-binding proteins have been identified as m^6A readers (6, 142–145). For example, subunits of the translation initiation factor complex eIF3 can bind to m^6A sites within 5' UTRs to promote cap-independent translation of cellular mRNAs in response to stress (145). Additionally, eIF3 is required for the translation of m^6A -containing circular RNAs, further indicating a role for m^6A in cap-independent translation, although this mechanism also involves YTHDF3 and eIF4G2 (146).

IGF2BP proteins (IGF2BP1, IGF2BP2, and IGF2BP3) have also been identified as m^6A readers. These proteins recognize m^6A through their K homology (KH) domains and act to promote mRNA stability and translation (144) (**Figure 3a**). IGF2BP proteins bind RNA at sequences similar to the m^6A consensus sequence, but interestingly, these sites are enriched throughout 3' UTRs as opposed to near the stop codon, as is typically observed for m^6A (144). Moreover, the selectivity of IGF2BP proteins for m^6A is much lower than that of YTH proteins (an approximately threefold increase in binding affinity for m^6A compared to A) (144). Another possibility is that IGF2BP proteins are indirect m^6A readers that bind RNA through m^6A -dependent structural changes (see Section 3.5), as has been demonstrated for IGF2BP3 (147).

The fragile X mental retardation protein (FMRP) is another protein that displays preferential m^6A binding (142). Similar to the IGF2BP proteins, FMRP exhibits a modest preference for binding m^6A compared to A (~2.5-fold increase in binding affinity) (148, 149), and evidence from CLIP-based analyses suggests that only a subset of FMRP targets are methylated (148, 150). Nevertheless, FMRP has been shown to regulate some mRNAs through m^6A . Many of these roles have been demonstrated in neurons, where FMRP contributes to mRNA export (149, 150), neuronal differentiation (149), and mRNA decay (148). However, FMRP can also directly interact with DF2, and at least part of its function in the control of mRNA stability could be through this interaction (148). Future studies are needed to better understand the m^6A -dependent and m^6A -independent functions of FMRP.

While the m^6A -binding activity of many m^6A readers is conserved across cell types (142), it is likely that cell-type- and tissue-specific readers exist. For example, PRRC2A has been identified as a reader in oligodendrocytes, where it binds RNAs at DRACH motifs and displays a binding pattern in mRNAs that matches the distribution of m^6A (151). PRRC2A plays an important role in oligodendrocyte differentiation and myelination by stabilizing the *Olig2* mRNA in an m^6A -dependent manner (151). Similarly, RBM45 is a brain-enriched m^6A -binding protein that influences splicing and neuronal differentiation (152). It will be interesting to see whether PRRC2A, RBM45, and other novel readers contribute to m^6A -mediated regulation in other cell types or whether there is cell-type-specific specialization in reader protein function. Additionally, m^6A likely plays important roles in RNA regulation by repelling RBPs. For example, the stress granule protein G3BP1 exhibits preferential binding to nonmethylated RNA in some sequence contexts, which in turn impacts RNA stability (142).

3.5. Indirect Readers

In addition to direct recognition of m^6A by RBPs, m^6A can influence RNA–protein interactions by altering RNA structure. m^6A can destabilize RNA duplexes by 0.5–1.7 kcal/mol through both a nonfavorable trans conformation when paired with U and improved stacking in its unpaired conformation (153). Thus, m^6A has the potential to act as a so-called m^6A switch, where it alters local RNA structure to enable, enhance, or prevent the binding of some RBPs (**Figure 3c**). The first example of this mechanism was the binding of heterogeneous nuclear ribonucleoprotein C

(HNRNPC) to a stem-loop within the lncRNA *MALAT1* (154). The presence of m⁶A within this region destabilizes the stem-loop and exposes an HNRNPC-binding site. Global analysis revealed nearly 2,800 binding sites of HNRNPC that are altered when m⁶A is depleted, resulting in changes in alternative splicing of target RNAs (154). Similar observations have since been made for HNRNPNG (155) and HNRNPA2B1 (156), suggesting that the m⁶A-switch mechanism may play an important role in splicing regulation in the nucleus. Additionally, global profiling of m⁶A-dependent structural changes has shown that many changes are conserved from the nucleus to the cytoplasm, suggesting that m⁶A-dependent structural changes are likely to impact mature mRNAs as well (147). Indeed, m⁶A can indirectly impact RNA recognition by HuR, which in turn mediates miRNA-mediated mRNA targeting to control mESC self-renewal (157).

3.6. Readers of Other Modifications

Readers of modifications other than m⁶A have also been identified, although in general these remain less well understood (**Figure 2**). For example, a recent study identified the metabolic enzyme HRSP12 as an m¹A reader that can cooperate with YTHDF2 and m⁶A to direct RNA degradation (158). However, it remains unclear how HRSP12 recognizes m¹A, as it lacks homology for known RBDs. Other studies have identified several m⁵C readers, including ALYREF, which plays a role in mRNA export (70); YBX1, which stabilizes target RNAs (159); and RAD52, which displays increased binding for m⁵C at sites of DNA repair (160). The mechanism by which these proteins recognize m⁵C differs among the proteins, including the involvement of a critical lysine residue in ALYREF and a cold-shock domain in YBX1 (70, 159). Thus, unlike the YTH domain proteins that bind m⁶A, currently identified m⁵C readers appear to utilize distinct domains to recognize m⁵C.

Readers of Ψ are also poorly understood. In *S. cerevisiae*, methionine aminoacyl tRNA^{Met} synthetase (MetRS) binds to Ψ not only in tRNAs but also in mRNAs, where it controls the translation of specific transcripts (161). Additionally, Martinez et al. (54) recently found that Ψ sites in pre-mRNAs are enriched for splicing factor binding sites. However, direct binding by these proteins was not characterized, and it is possible that they bind indirectly to Ψ -modified RNAs.

Much of the impact of mRNA modifications on gene expression is due to their influence on RNA-protein interactions. Thus, it will be important going forward to identify reader proteins for individual modifications and to determine how specific modified residues alter RNA recognition either directly or indirectly. For many modifications, such studies are still in their infancy. For instance, in vitro RNA pulldown studies identified TBL3 as a potential reader protein for ac⁴C (162), but this interaction and potential functional implications have yet to be validated in cells.

4. ERASER PROTEINS

The possibility that RNA modifications can be reversible has important implications for modification dynamics in cells and, in turn, the influence of a particular modification on gene expression. The discovery of eraser proteins that can remove various modifications has opened up new avenues of research into the targets of these proteins and the consequences of modification removal for RNA processing and cellular function.

4.1. FTO

Shortly before the first transcriptome-wide m⁶A mapping studies were published, FTO (fat mass and obesity-associated) was discovered as an m⁶A demethylase that could remove m⁶A from RNA (7). This was an important finding for the still nascent epitranscriptomics field since it suggested that chemical modifications could potentially be susceptible to dynamic regulation.

FTO is a member of the Fe(II) and 2-oxoglutarate-dependent dioxygenase family of proteins, which encodes homologs of the bacterial ALKB enzyme that function in DNA and RNA repair (163). In addition to removing m^6A from RNA *in vitro*, FTO was shown to influence m^6A levels in mRNAs in cells and *in vivo* (7, 164). Subsequent studies shed light on the mechanism through which FTO demethylates m^6A and found that it does so through the production of N^6 -hydroxymethyladenosine and N^6 -formyladenosine intermediates (165). FTO lacks general sequence specificity for m^6A , but its demethylation activity can be influenced by m^6A -dependent conformational changes, such that much higher activity is seen when m^6A is in a single-stranded or hairpin structure compared to a duplex (166, 167). This structural preference may explain why many m^6A sites do not seem to be affected by FTO. Indeed, FTO knockout does not lead to dramatic hypermethylation of all m^6A sites (164, 168), and its overexpression in cells often has only small effects on lowering global m^6A levels (169).

An important shift in our understanding of FTO came in 2017, when Mauer et al. (83) reported that FTO can demethylate m^6A_m (**Figure 4**). This study further showed that FTO removes m^6A_m much more efficiently than m^6A *in vitro* and preferentially targets m^6A_m over m^6A in cells. These findings reshaped the view of FTO as exclusively an m^6A demethylase and prompted additional studies into the true targets of FTO in cells.




Figure 4

Targets of m^6A eraser proteins. (a) In the nucleus, FTO and ALKBH5 demethylate m^6A sites in mRNAs. FTO can also remove m^6A and m^6A_m in lncRNAs and snRNAs. (b) In the cytoplasm, FTO can remove m^6A and m^6A_m from mRNAs and m^1A from tRNA. In the nervous system, FTO expression is regulated by activity and can promote m^6A demethylation of specific transcripts in axons. ALKBH5 expression is increased in hypoxic conditions and in cancer cells, resulting in decreased m^6A levels of specific mRNAs and enhanced cell proliferation and stem cell self-renewal. Abbreviations: ALKBH, AlkB homolog; A_m , 2'-*O*-methyladenosine; FTO, fat mass and obesity-associated; LINE1, long-interspersed element-1; lncRNA, long noncoding RNA; m^1A , N^1 -methyladenosine; m^6A , N^6 -methyladenosine; m^6A_m , $N^6,2'$ -*O*-dimethyladenosine; m^7G , N^7 -methylguanosine; snRNA, small nuclear RNA.

The substrate preference of FTO appears to be affected in part by differences in expression levels and subcellular localization of FTO across different cell types. Initial reports characterized FTO as a nuclear protein (7), but subsequent studies have shown that it can be localized to the cytoplasm in some cell types (170, 171). FTO has also been reported in neuronal synaptic compartments and in axons of cultured neurons, where it may mediate local demethylation of select mRNAs (130, 172) (**Figure 4b**). Analysis of FTO demethylation in various immortalized cell lines and subcellular regions revealed that FTO has a preference for demethylating m⁶A in the nucleus and m⁶A and m⁶A_m in the cytoplasm in polyadenylated RNA, as well as m¹A in tRNA (170) (**Figure 4a,b**). Thus, in some cell lines such as HeLa and HEK293T, where FTO is largely nuclear, the effects of FTO depletion on m⁶A_m are less pronounced, perhaps because access to m⁶A_m is blocked by the nuclear cap-binding complex. Indeed, forced expression of FTO in the cytoplasm leads to higher levels of m⁶A_m demethylation compared to m⁶A (83, 170).

Dynamic regulation of FTO localization may be a mechanism for cells to selectively regulate m⁶A and m⁶A_m levels. Alteration of FTO subcellular localization has been observed in the brain in response to starvation and fear conditioning (173, 174). FTO PTMs may also impact its subcellular localization in response to stress (175). More research is needed to determine whether other stimuli influence nuclear and cytoplasmic FTO levels and if this corresponds to selective demethylation of m⁶A or m⁶A_m.

Recent studies also suggest that mRNAs may not be the primary targets of FTO: In line with the predominantly nuclear localization of FTO in many cell types, snRNAs have been identified as FTO targets, with FTO depletion causing increased m⁶A_m in snRNAs (168, 176) (**Figure 4a**). snRNAs are an important class of splicing regulatory transcripts, and reduction in FTO has been shown to result in altered splicing, potentially mediated by its impact on snRNA expression (168, 176, 177). Additionally, m⁶A in long-interspersed element-1 (LINE1) RNAs has been shown to be targeted by FTO in mESCs (178) (**Figure 4a**). Loss of FTO causes elevated LINE1 methylation, leading to repression of LINE1 RNA and alterations to the chromatin state and gene expression, which impacts oocyte maturation and embryonic development (178). Thus, removal of m⁶A and m⁶A_m in nuclear noncoding RNAs appears to be an important aspect of FTO's demethylase activity.

Numerous studies have linked FTO to human disease. In 2007, genome-wide association studies found that mutations clustering within intron 1 of *FTO* were associated with increased body mass index and risk for obesity (179). Since then, multiple studies have found associations between genetic variants in *FTO* and obesity and related phenotypes (180). Importantly, some obesity-associated mutations within *FTO* have also been found to impact long-range genomic interactions with other genes such as *IRX3*, suggesting that the disease links of these mutations may not be mediated through the *FTO* protein itself (181). However, mice with either missense *Fto* mutations or gain/loss of *FTO* expression exhibit metabolic phenotypes and developmental defects, so it is likely that misregulation of the *FTO* protein is a contributing factor to obesity-related diseases (180).

In addition to its links to obesity and metabolism, *FTO* has been associated with several other diseases, including Alzheimer's disease (182, 183), neuropsychiatric disorders (184), and various cancers (180, 185). *FTO* expression is upregulated in some acute myeloid leukemia (AML) subtypes, where it promotes leukemogenesis and inhibits leukemia cell differentiation (186, 187). *FTO* can also be inhibited by the oncometabolite 2-hydroxyglutarate (2HG) and has been shown to mediate antitumor effects in 2HG-sensitive cells through the MYC/CEBPA signaling pathway (187). *FTO* has also been implicated in glioblastoma, as its inhibition impairs glioblastoma stem cell (GSC) growth and self-renewal and leads to decreased tumor growth in mice. This is accompanied by decreased expression of oncogenes such as *ADAM19* (188). Collectively, these studies

point to FTO as a potential therapeutic target and suggest cell-type-specific pathways that may be regulated by FTO to contribute to disease. However, FTO has been shown to play both positive and negative roles in cancer progression (185), so continued investigation of the cellular target RNAs of FTO is important for determining its value as a therapeutic target in specific cell types. It is also important to better understand whether FTO's effects on a particular RNAs expression are mediated through m⁶A or m⁶A_m demethylation.

Recent work has uncovered potential roles for FTO as a mechanism for increasing biomass and yield in plants. Early studies in *Arabidopsis* first demonstrated that m⁶A is required for normal plant development (18, 189), indicating that proper m⁶A regulation is required for plant growth. Although plants lack an FTO homolog, overexpression of human FTO causes m⁶A demethylation and promotes chromatin accessibility and transcriptional activation, ultimately leading to substantial increases in plant growth (190). This is an emerging area of research with important implications for increasing crop yield.

4.2. ALKBH5

ALKBH5 was the second m⁶A demethylase enzyme to be discovered and is also a member of the iron- and 2-OG-dependent family of dioxygenase enzymes (191). ALKBH5 localizes to nuclear speckles and carries out demethylation of nuclear RNA substrates, and ALKBH5 depletion has been shown to impact nuclear mRNA export (191). Structural studies have provided insights into the mechanism of m⁶A binding and have shown that, like FTO, ALKBH5 prefers single-stranded substrates (166, 192–194). However, unlike FTO, ALKBH5 does not have reported activity on m⁶A_m, thus making it likely that m⁶A is its only substrate (83) (**Figure 4a**).

The expression pattern of ALKBH5 across tissues is distinct from that of FTO. ALKBH5 is highly abundant in testis, and *Alkbb5* knockout mice have impaired spermatogenesis and decreased male fertility (191). *Alkbb5* knockout mice otherwise appear normal, suggesting that a primary function for *Alkbb5* is to mediate m⁶A levels during gametogenesis. However, roles for ALKBH5 in other tissues may still be possible, especially through targeting of specific transcripts. For instance, conditional knockout of *Alkbb5* in bone marrow mesenchymal stem cells (MSCs) has been shown to regulate MSC differentiation and bone mass through regulation of *Prmt6* (195).

Several studies have linked altered levels of ALKBH5 with human disease. For instance, ALKBH5 is upregulated in breast cancer cells in response to a hypoxic environment, which alters m⁶A levels and abundance of the pluripotency factor *NANOG* to promote breast cancer stem cell growth (196). ALKBH5 is also elevated in glioblastoma, where it impacts GSC proliferation through modulation of *FOXMI* levels (197). Consistent with roles for m⁶A in AML progression, ALKBH5 levels are also increased in AML and associated with poor prognosis (185) (**Figure 4b**).

The discovery of m⁶A demethylase enzymes suggests the possibility that demethylation of mRNAs in the cytoplasm can be a mechanism for dynamic m⁶A regulation. As discussed in Section 4.1, there are studies that suggest that this may be true for specific transcripts. However, an alternative model is that demethylases do not dynamically regulate cytoplasmic m⁶A but instead act to remove m⁶A sites in the nucleus shortly after their formation in order to maintain these sites in a persistently unmethylated state. This model is supported by evidence from a nucleotide-resolution m⁶A mapping study which found that knockout of either ALKBH5 or FTO causes new sites to emerge, instead of leading to hypermethylation of existing sites. This suggests that demethylase-regulated sites are normally present only transiently and thus fail to be detected in wild-type cells. However, this idea is countered by several studies that have found that ALKBH5 or FTO depletion is accompanied by only minor increases in m⁶A (83, 164, 191). Going forward, it will be important to understand whether m⁶A demethylation serves to correct

initial transcript methylation or if it acts as a mechanism for dynamic regulation of RNAs. In either case, current evidence suggests that the impact of FTO and ALKBH5 on global m⁶A is for the most part modest but that demethylation of specific transcripts may have important outcomes for cellular function in distinct cellular states or cell types.

4.3. Erasers of Other Modifications

In addition to FTO and ALKBH5, other members of the ALKB family of dioxygenase enzymes have been found to demethylate modified RNAs. For instance, ALKBH1 can remove m¹A from tRNAs (198), and ALKBH3 can demethylate m¹A residues in mRNA and tRNA (59, 199) (**Figure 2**). Both of these enzymes have demethylase activity on other modifications as well (200). As discussed in Section 2.5, there have been conflicting reports regarding the prevalence of m¹A in cellular mRNAs. Although it seems clear that mitochondrial mRNAs can be m¹A modified, it is unknown whether ALKBH3 acts on these transcripts.

The ten-eleven translocation (TET) family of dioxygenase proteins (TET1, TET2, and TET3) has been well characterized for their ability to convert 5-methylcytosine in DNA to 5-hydroxymethylcytosine (5hmC) (201). Additionally, TETs are capable of converting m⁵C to 5hmC in RNA (202, 203) (**Figure 2**). 5hmC is detectable in cellular mRNAs (203–205), suggesting that it is not a transient product but instead can have its own functions. Indeed, studies in flies indicate roles for 5hmC in promoting translation and regulating brain development (203), and cytosine hydroxymethylation in mESCs leads to reduced stability of pluripotency-related transcripts which may be important during differentiation (205).

5. CONCLUDING REMARKS

Although mRNA modifications were first detected nearly 50 years ago, recent technical advances in identifying modified nucleotides have fueled rapid progress in our understanding of their regulation and biological impact, particularly for m⁶A. However, important questions remain. For modifications other than m⁶A, m⁶A_m, and ψ , some discrepancies remain regarding their abundance in cellular mRNAs. The development of more reliable profiling methods is important for determining the location and stoichiometry of these modifications and enabling consistency across studies. Researchers have made substantial progress in the development of novel modification detection methods over the past few years, including the use of direct RNA sequencing, which holds great promise for the detection of diverse modifications within individual RNA molecules. Still, there are substantial challenges that still need to be overcome, in particular for mapping modifications with low abundance.

Although many core components of the m⁶A MTC have been identified, our understanding of the precise mechanisms that direct methylation of specific consensus motifs remains incomplete. Some evidence suggests that RNA structure may make a minor contribution (29). The distribution of m⁶A, characterized by depletion near exon boundaries and enrichment in long internal exons and near the beginning of terminal exons (6, 30–33), has also suggested that gene architecture plays a role. Now, it is clear that the EJC helps shape methylation by limiting m⁶A deposition near splice junctions (31–33). Transcription factors and histone modifications also help recruit the MTC to specific transcripts (34–37), which suggests that methylation of some RNAs can be guided by cell- and context-specific factors. Additionally, it is important to note that much of our current knowledge of the factors driving mRNA methylation comes from studies in bulk cells. Our group recently profiled m⁶A in single cells and found that mRNAs contain many m⁶A sites, most of which occur relatively rarely throughout the population of cells (42). This suggests either that there is high variability in methylation site selection between cells or that the methylation of

specific residues may not be as critical as methylation of transcript regions. Continued studies of m⁶A in single cells, especially in tissues or in response to changing cellular states, will be critical for improving our understanding of m⁶A distribution and regulation.

Another area of high importance is the study of m⁶A reader proteins, including the YTHDF proteins. Work in mESCs as well as in HeLa and HEK293 cell lines suggests that all three DF family proteins interact with similar proteins and are functionally redundant in contributing to the degradation of transcripts (95, 117). However, other studies have shown that different DF proteins can have distinct interacting partners, and there is also a body of evidence for DF-specific effects in the nervous system. It will be important to consider the extent to which reader proteins are functionally redundant within different biological contexts. Furthermore, methods for dissecting single-molecule DF–protein interactions will be important for illuminating how the three DF proteins compete or cooperate in cells to bind to m⁶A sites.

Questions also remain about the functions of m⁶A eraser proteins, in particular FTO. While m⁶A was predicted to be a dynamic modification after the discovery of FTO as an m⁶A demethylase, the generality of this assumption has since been challenged. FTO is now known to play important roles in the demethylation of m⁶A_m (83), and its effects on m⁶A are likely to be transcript and perhaps cell-type specific. ALKBH5 is largely nuclear and plays its most important biological roles in male germ cell development (191). This suggests that m⁶A may not be as generally dynamic—at least in the sense of widespread active removal—as previously thought. As with so many other aspects of m⁶A, defining the cell types, cellular states, and specific transcripts that are targeted for demethylation will be important for a more complete understanding of the physiological importance of m⁶A demethylation and for our views of m⁶A dynamics.

DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS

We would like to thank members of the Meyer Lab for helpful discussions while this article was in preparation. This work was supported by the Rita Allen Foundation and the National Institutes of Health (grants R01MH118366 and DP1DA046584 to K.D.M.).

LITERATURE CITED

1. Desrosiers R, Friderici K, Rottman F. 1974. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. *PNAS* 71:3971–75
2. Perry RP, Kelley DE. 1974. Existence of methylated messenger RNA in mouse L cells. *Cell* 1:37–42
3. Wei CM, Gershowitz A, Moss B. 1976. 5'-terminal and internal methylated nucleotide sequences in HeLa cell mRNA. *Biochemistry* 15:397–401
4. Wei CM, Moss B. 1977. Nucleotide sequences at the N⁶-methyladenosine sites of HeLa cell messenger ribonucleic acid. *Biochemistry* 16:1672–76
5. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. 2012. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* 149:1635–46
6. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, et al. 2012. Topology of the human and mouse m⁶A RNA methylomes revealed by m⁶A-seq. *Nature* 485:201–6
7. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, et al. 2011. N⁶-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat. Chem. Biol.* 7:885–87
8. Harper JE, Miceli SM, Roberts RJ, Manley JL. 1990. Sequence specificity of the human mRNA N⁶-adenosine methylase in vitro. *Nucleic Acids Res.* 18:5735–41

9. Bokar JA, Rath-Shambaugh ME, Ludwiczak R, Narayan P, Rottman F. 1994. Characterization and partial purification of mRNA N⁶-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. *J. Biol. Chem.* 269:17697–704
10. Bokar JA, Shambaugh ME, Polayes D, Matera AG, Rottman FM. 1997. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N⁶-adenosine)-methyltransferase. *RNA* 3:1233–47
11. Liu J, Yue Y, Han D, Wang X, Fu Y, et al. 2014. A METTL3-METTL14 complex mediates mammalian nuclear RNA N⁶-adenosine methylation. *Nat. Chem. Biol.* 10:93–95
12. Sledz P, Jinek M. 2016. Structural insights into the molecular mechanism of the m⁶A writer complex. *eLife* 5:e18434
13. Wang P, Doxtader KA, Nam Y. 2016. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. *Mol. Cell* 63:306–17
14. Wang X, Feng J, Xue Y, Guan Z, Zhang D, et al. 2016. Structural basis of N⁶-adenosine methylation by the METTL3-METTL14 complex. *Nature* 534:575–78
15. Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K, et al. 2014. Perturbation of m⁶A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. *Cell Rep.* 8:284–96
16. Lin S, Choe J, Du P, Triboulet R, Gregory RI. 2016. The m⁶A methyltransferase METTL3 promotes translation in human cancer cells. *Mol. Cell* 62:335–45
17. Choe J, Lin S, Zhang W, Liu Q, Wang L, et al. 2018. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. *Nature* 561:556–60
18. Zhong S, Li H, Bodi Z, Button J, Vespa L, et al. 2008. MTA is an Arabidopsis messenger RNA adenosine methylase and interacts with a homolog of a sex-specific splicing factor. *Plant Cell* 20:1278–88
19. Agarwala SD, Blitzblau HG, Hochwagen A, Fink GR. 2012. RNA methylation by the MIS complex regulates a cell fate decision in yeast. *PLoS Genet.* 8:e1002732
20. Ping XL, Sun BF, Wang L, Xiao W, Yang X, et al. 2014. Mammalian WTAP is a regulatory subunit of the RNA N⁶-methyladenosine methyltransferase. *Cell Res.* 24:177–89
21. Yue Y, Liu J, Cui X, Cao J, Luo G, et al. 2018. VIRMA mediates preferential m⁶A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. *Cell Discov.* 4:10
22. Horiuchi K, Kawamura T, Iwanari H, Ohashi R, Naito M, et al. 2013. Identification of Wilms' tumor 1-associated protein complex and its role in alternative splicing and the cell cycle. *J. Biol. Chem.* 288:33292–302
23. Ortega A, Niksic M, Bachi A, Wilm M, Sanchez L, et al. 2003. Biochemical function of female-lethal (2)D/Wilms' tumor suppressor-1-associated proteins in alternative pre-mRNA splicing. *J. Biol. Chem.* 278:3040–47
24. Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, et al. 2016. m⁶A RNA methylation promotes XIST-mediated transcriptional repression. *Nature* 537:369–73
25. Wang Y, Zhang L, Ren H, Ma L, Guo J, et al. 2021. Role of Hakai in m⁶A modification pathway in *Drosophila*. *Nat. Commun.* 12:2159
26. Bawankar P, Lence T, Paolantoni C, Haussmann IU, Kazlauskienė M, et al. 2021. Hakai is required for stabilization of core components of the m⁶A mRNA methylation machinery. *Nat. Commun.* 12:3778
27. Ruzicka K, Zhang M, Campilho A, Bodi Z, Kashif M, et al. 2017. Identification of factors required for m⁶A mRNA methylation in *Arabidopsis* reveals a role for the conserved E3 ubiquitin ligase HAKAI. *New Phytol.* 215:157–72
28. Wen J, Lv R, Ma H, Shen H, He C, et al. 2018. Zc3h13 regulates nuclear RNA m⁶A methylation and mouse embryonic stem cell self-renewal. *Mol. Cell* 69:1028–38.e6
29. Garcia-Campos MA, Edelheit S, Toth U, Safra M, Shachar R, et al. 2019. Deciphering the “m⁶A Code” via antibody-independent quantitative profiling. *Cell* 178:731–47.e16
30. Ke S, Alemu EA, Mertens C, Gantman EC, Fak JJ, et al. 2015. A majority of m⁶A residues are in the last exons, allowing the potential for 3' UTR regulation. *Genes Dev.* 29:2037–53
31. Uzonyi A, Dierks D, Nir R, Kwon OS, Toth U, et al. 2023. Exclusion of m⁶A from splice-site proximal regions by the exon junction complex dictates m⁶A topologies and mRNA stability. *Mol. Cell* 83:237–51.e7

32. Yang X, Triboulet R, Liu Q, Sendinc E, Gregory RI. 2022. Exon junction complex shapes the m⁶A epitranscriptome. *Nat. Commun.* 13:7904
33. He PC, Wei J, Dou X, Harada BT, Zhang Z, et al. 2023. Exon architecture controls mRNA m⁶A suppression and gene expression. *Science* 379:677–82
34. Huang H, Weng H, Zhou K, Wu T, Zhao BS, et al. 2019. Histone H3 trimethylation at lysine 36 guides m⁶A RNA modification co-transcriptionally. *Nature* 567:414–19
35. Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, et al. 2017. Promoter-bound METTL3 maintains myeloid leukaemia by m⁶A-dependent translation control. *Nature* 552:126–31
36. Bertero A, Brown S, Madrigal P, Osnato A, Ortmann D, et al. 2018. The SMAD2/3 interactome reveals that TGFβ controls m⁶A mRNA methylation in pluripotency. *Nature* 555:256–59
37. Raj N, Wang M, Seoane JA, Zhao RL, Kaiser AM, et al. 2022. The Mettl3 epitranscriptomic writer amplifies p53 stress responses. *Mol. Cell* 82:2370–84.e10
38. Slobodin B, Han R, Calderone V, Vrielink J, Loayza-Puch F, et al. 2017. Transcription impacts the efficiency of mRNA translation via co-transcriptional N⁶-adenosine methylation. *Cell* 169:326–37.e12
39. Jonkers I, Lis JT. 2015. Getting up to speed with transcription elongation by RNA polymerase II. *Nat. Rev. Mol. Cell Biol.* 16:167–77
40. Liu J, Li K, Cai J, Zhang M, Zhang X, et al. 2020. Landscape and regulation of m⁶A and m⁶Am methylome across human and mouse tissues. *Mol. Cell* 77:426–40.e6
41. Yin R, Chang J, Li Y, Gao Z, Qiu Q, et al. 2022. Differential m⁶A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function. *Cell Stem Cell* 29:149–59.e7
42. Tegowski M, Flamand MN, Meyer KD. 2022. scDART-seq reveals distinct m⁶A signatures and mRNA methylation heterogeneity in single cells. *Mol. Cell* 82:868–78.e10
43. Du Y, Hou G, Zhang H, Dou J, He J, et al. 2018. SUMOylation of the m⁶A-RNA methyltransferase METTL3 modulates its function. *Nucleic Acids Res.* 46:5195–208
44. Wang Z, Pan Z, Adhikari S, Harada BT, Shen L, et al. 2021. m⁶A deposition is regulated by PRMT1-mediated arginine methylation of METTL14 in its disordered C-terminal region. *EMBO J.* 40:e106309
45. Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y, et al. 2017. The U6 snRNA m⁶A methyltransferase METTL16 regulates SAM synthetase intron retention. *Cell* 169:824–35.e14
46. Warda AS, Kretschmer J, Hackert P, Lenz C, Urlaub H, et al. 2017. Human METTL16 is a N⁶-methyladenosine (m⁶A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. *EMBO Rep.* 18:2004–14
47. Brown JA, Kinzig CG, DeGregorio SJ, Steitz JA. 2016. Methyltransferase-like protein 16 binds the 3'-terminal triple helix of MALAT1 long noncoding RNA. *PNAS* 113:14013–18
48. Mendel M, Delaney K, Pandey RR, Chen KM, Wenda JM, et al. 2021. Splice site m⁶A methylation prevents binding of U2AF35 to inhibit RNA splicing. *Cell* 184:3125–42.e25
49. Watabe E, Togo-Ohno M, Ishigami Y, Wani S, Hirota K, et al. 2021. m⁶A-mediated alternative splicing coupled with nonsense-mediated mRNA decay regulates SAM synthetase homeostasis. *EMBO J.* 40:e106434
50. Su R, Dong L, Li Y, Gao M, He PC, et al. 2022. METTL16 exerts an m⁶A-independent function to facilitate translation and tumorigenesis. *Nat. Cell Biol.* 24:205–16
51. Li X, Zhu P, Ma S, Song J, Bai J, et al. 2015. Chemical pulldown reveals dynamic pseudouridylation of the mammalian transcriptome. *Nat. Chem. Biol.* 11:592–97
52. Carlile TM, Rojas-Duran MF, Zinshteyn B, Shin H, Bartoli KM, Gilbert WV. 2014. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. *Nature* 515:143–46
53. Schwartz S, Bernstein DA, Mumbach MR, Jovanovic M, Herbst RH, et al. 2014. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. *Cell* 159:148–62
54. Martinez NM, Su A, Burns MC, Nussbacher JK, Schaening C, et al. 2022. Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect pre-mRNA processing. *Mol. Cell* 82:645–59.e9
55. Karijolich J, Yu YT. 2011. Converting nonsense codons into sense codons by targeted pseudouridylation. *Nature* 474:395–98
56. Ozanick S, Krecic A, Andersland J, Anderson JT. 2005. The bipartite structure of the tRNA m1A58 methyltransferase from *S. cerevisiae* is conserved in humans. *RNA* 11:1281–90

57. Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, et al. 2017. The m¹A landscape on cytosolic and mitochondrial mRNA at single-base resolution. *Nature* 551:251–55
58. Grozhik AV, Olarerin-George AO, Sindelar M, Li X, Gross SS, Jaffrey SR. 2019. Antibody cross-reactivity accounts for widespread appearance of m¹A in 5'UTRs. *Nat. Commun.* 10:5126
59. Li X, Xiong X, Wang K, Wang L, Shu X, et al. 2016. Transcriptome-wide mapping reveals reversible and dynamic N¹-methyladenosine methylome. *Nat. Chem. Biol.* 12:311–16
60. Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, et al. 2016. The dynamic N¹-methyladenosine methylome in eukaryotic messenger RNA. *Nature* 530:441–46
61. Arango D, Sturgill D, Yang R, Kanai T, Bauer P, et al. 2022. Direct epitranscriptomic regulation of mammalian translation initiation through N⁴-acetylcytidine. *Mol. Cell* 82:2797–814.e11
62. Arango D, Sturgill D, Alhusaini N, Dillman AA, Sweet TJ, et al. 2018. Acetylation of cytidine in mRNA promotes translation efficiency. *Cell* 175:1872–86.e24
63. Guo G, Shi X, Wang H, Ye L, Tong X, et al. 2020. Epitranscriptomic N⁴-acetylcytidine profiling in CD4⁺ T cells of systemic lupus erythematosus. *Front. Cell Dev. Biol.* 8:842
64. Dubin DT, Taylor RH. 1975. The methylation state of poly A-containing messenger RNA from cultured hamster cells. *Nucleic Acids Res.* 2:1653–68
65. Squires JE, Patel HR, Nousch M, Sibbritt T, Humphreys DT, et al. 2012. Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. *Nucleic Acids Res.* 40:5023–33
66. Legrand C, Tuorto F, Hartmann M, Liebers R, Jacob D, et al. 2017. Statistically robust methylation calling for whole-transcriptome bisulfite sequencing reveals distinct methylation patterns for mouse RNAs. *Genome Res.* 27:1589–96
67. Huang T, Chen W, Liu J, Gu N, Zhang R. 2019. Genome-wide identification of mRNA 5-methylcytosine in mammals. *Nat. Struct. Mol. Biol.* 26:380–88
68. Khoddami V, Yerra A, Mosbrugger TL, Fleming AM, Burrows CJ, Cairns BR. 2019. Transcriptome-wide profiling of multiple RNA modifications simultaneously at single-base resolution. *PNAS* 116:6784–89
69. Fang L, Wang W, Li G, Zhang L, Li J, et al. 2020. CIGAR-seq, a CRISPR/Cas-based method for unbiased screening of novel mRNA modification regulators. *Mol. Syst. Biol.* 16:e10025
70. Yang X, Yang Y, Sun BF, Chen YS, Xu JW, et al. 2017. 5-methylcytosine promotes mRNA export—NSUN2 as the methyltransferase and ALYREF as an m⁵C reader. *Cell Res.* 27:606–25
71. Blanco S, Frye M. 2014. Role of RNA methyltransferases in tissue renewal and pathology. *Curr. Opin. Cell Biol.* 31:1–7
72. Bohnsack KE, Hobartner C, Bohnsack MT. 2019. Eukaryotic 5-methylcytosine (m⁵C) RNA methyltransferases: mechanisms, cellular functions, and links to disease. *Genes* 10:E102
73. Decatur WA, Fournier MJ. 2003. RNA-guided nucleotide modification of ribosomal and other RNAs. *J. Biol. Chem.* 278:695–98
74. Dai Q, Moshitch-Moshkovitz S, Han D, Kol N, Amariglio N, et al. 2017. Nm-seq maps 2'-O-methylation sites in human mRNA with base precision. *Nat. Methods* 14:695–98
75. Omer AD, Ziesche S, Ebhardt H, Dennis PP. 2002. In vitro reconstitution and activity of a C/D box methylation guide ribonucleoprotein complex. *PNAS* 99:5289–94
76. Elliott BA, Ho HT, Ranganathan SV, Vangaveti S, Ilkayeva O, et al. 2019. Modification of messenger RNA by 2'-O-methylation regulates gene expression in vivo. *Nat. Commun.* 10:3401
77. Belanger F, Stepinski J, Darzynkiewicz E, Pelletier J. 2010. Characterization of hMT1, a human Cap1 2'-O-ribose methyltransferase. *J. Biol. Chem.* 285:33037–44
78. Furuichi Y, Morgan M, Shatkin AJ, Jelinek W, Salditt-Georgieff M, Darnell JE. 1975. Methylated, blocked 5' termini in HeLa cell mRNA. *PNAS* 72:1904–8
79. Wei C, Gershowitz A, Moss B. 1975. N⁶, O^{2'}-dimethyladenosine a novel methylated ribonucleoside next to the 5' terminal of animal cell and virus mRNAs. *Nature* 257:251–53
80. Boulias K, Toczydlowska-Socha D, Hawley BR, Liberman N, Takashima K, et al. 2019. Identification of the m⁶Am methyltransferase PCIF1 reveals the location and functions of m⁶Am in the transcriptome. *Mol. Cell* 75:631–43.e8
81. Sendinc E, Valle-Garcia D, Dhall A, Chen H, Henriques T, et al. 2019. PCIF1 catalyzes m⁶Am mRNA methylation to regulate gene expression. *Mol. Cell* 75:620–30.e9

82. Ben-Haim MS, Pinto Y, Moshitch-Moshkovitz S, Hershkovitz V, Kol N, et al. 2021. Dynamic regulation of N⁶,2'-O-dimethyladenosine (m⁶Am) in obesity. *Nat. Commun.* 12:7185
83. Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik AV, et al. 2017. Reversible methylation of m⁶A_m in the 5' cap controls mRNA stability. *Nature* 541:371–75
84. Kruse S, Zhong S, Bodi Z, Button J, Alcocer MJ, et al. 2011. A novel synthesis and detection method for cap-associated adenosine modifications in mouse mRNA. *Sci. Rep.* 1:126
85. Stoilov P, Rafalska I, Stamm S. 2002. YTH: a new domain in nuclear proteins. *Trends Biochem. Sci.* 27:495–97
86. Zhang Z, Theler D, Kaminska KH, Hiller M, de la Grange P, et al. 2010. The YTH domain is a novel RNA binding domain. *J. Biol. Chem.* 285:14701–10
87. Wang C, Zhu Y, Bao H, Jiang Y, Xu C, et al. 2016. A novel RNA-binding mode of the YTH domain reveals the mechanism for recognition of determinant of selective removal by Mmi1. *Nucleic Acids Res.* 44:969–82
88. Schwartz S, Agarwala SD, Mumbach MR, Jovanovic M, Mertins P, et al. 2013. High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. *Cell* 155:1409–21
89. Li F, Zhao D, Wu J, Shi Y. 2014. Structure of the YTH domain of human YTHDF2 in complex with an m⁶A mononucleotide reveals an aromatic cage for m⁶A recognition. *Cell Res.* 24:1490–92
90. Zhu T, Roundtree IA, Wang P, Wang X, Wang L, et al. 2014. Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N⁶-methyladenosine. *Cell Res.* 24:1493–96
91. Xu C, Wang X, Liu K, Roundtree IA, Tempel W, et al. 2014. Structural basis for selective binding of m⁶A RNA by the YTHDC1 YTH domain. *Nat. Chem. Biol.* 10:927–29
92. Luo S, Tong L. 2014. Molecular basis for the recognition of methylated adenines in RNA by the eukaryotic YTH domain. *PNAS* 111:13834–39
93. Theler D, Dominguez C, Blatter M, Boudet J, Allain FH. 2014. Solution structure of the YTH domain in complex with N⁶-methyladenosine RNA: a reader of methylated RNA. *Nucleic Acids Res.* 42:13911–19
94. Xu C, Liu K, Ahmed H, Loppnau P, Schapira M, Min J. 2015. Structural basis for the discriminative recognition of N⁶-methyladenosine RNA by the human YT521-B homology domain family of proteins. *J. Biol. Chem.* 290:24902–13
95. Zaccara S, Jaffrey SR. 2020. A unified model for the function of YTHDF proteins in regulating m⁶A-modified mRNA. *Cell* 181:1582–95.e18
96. Liu B, Merriman DK, Choi SH, Schumacher MA, Plangger R, et al. 2018. A potentially abundant junctional RNA motif stabilized by m⁶A and Mg²⁺. *Nat. Commun.* 9:2761
97. Nayler O, Hartmann AM, Stamm S. 2000. The ER repeat protein YT521-B localizes to a novel subnuclear compartment. *J. Cell Biol.* 150:949–62
98. Hartmann AM, Nayler O, Schwaiger FW, Obermeier A, Stamm S. 1999. The interaction and colocalization of Sam68 with the splicing-associated factor YT521-B in nuclear dots is regulated by the Src family kinase p59(fyn). *Mol. Biol. Cell* 10:3909–26
99. Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, et al. 2016. Nuclear m⁶A reader YTHDC1 regulates mRNA splicing. *Mol. Cell* 61:507–19
100. Cheng Y, Xie W, Pickering BF, Chu KL, Savino AM, et al. 2021. N⁶-methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. *Cancer Cell* 39:958–72.e8
101. Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, et al. 2017. YTHDC1 mediates nuclear export of N⁶-methyladenosine methylated mRNAs. *eLife* 6:e31311
102. Kasowitz SD, Ma J, Anderson SJ, Leu NA, Xu Y, et al. 2018. Nuclear m⁶A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development. *PLOS Genet.* 14:e1007412
103. Zhang C, Chen L, Peng D, Jiang A, He Y, et al. 2020. METTL3 and N⁶-methyladenosine promote homologous recombination-mediated repair of DSBs by modulating DNA-RNA hybrid accumulation. *Mol. Cell* 79:425–42.e7
104. Liu J, Gao M, He J, Wu K, Lin S, et al. 2021. The RNA m⁶A reader YTHDC1 silences retrotransposons and guards ES cell identity. *Nature* 591:322–26

105. Li Y, Xia L, Tan K, Ye X, Zuo Z, et al. 2020. *N*⁶-methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2. *Nat. Genet.* 52:870–77
106. Liu J, Dou X, Chen C, Chen C, Liu C, et al. 2020. *N*⁶-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. *Science* 367:580–86
107. Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, et al. 2017. Ythdc2 is an *N*⁶-methyladenosine binding protein that regulates mammalian spermatogenesis. *Cell Res.* 27:1115–27
108. Wojtas MN, Pandey RR, Mendel M, Homolka D, Sachidanandam R, Pillai RS. 2017. Regulation of m⁶A transcripts by the 3'→5' RNA helicase YTHDC2 is essential for a successful meiotic program in the mammalian germline. *Mol. Cell* 68:374–87.e12
109. Tanabe A, Tanikawa K, Tsunetomi M, Takai K, Ikeda H, et al. 2016. RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which *HIF-1α* mRNA is translated. *Cancer Lett.* 376:34–42
110. Saito Y, Hawley BR, Puno MR, Sarathy SN, Lima CD, et al. 2022. YTHDC2 control of gametogenesis requires helicase activity but not m⁶A binding. *Genes Dev.* 36:180–94
111. Li L, Krasnykov K, Homolka D, Gos P, Mendel M, et al. 2022. The XRN1-regulated RNA helicase activity of YTHDC2 ensures mouse fertility independently of m⁶A recognition. *Mol. Cell* 82:1678–90.e12
112. Ries RJ, Zaccara S, Klein P, Olarerin-George A, Namkoong S, et al. 2019. m⁶A enhances the phase separation potential of mRNA. *Nature* 571:424–28
113. Fu Y, Zhuang X. 2020. m⁶A-binding YTHDF proteins promote stress granule formation. *Nat. Chem. Biol.* 16:955–63
114. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, et al. 2014. *N*⁶-methyladenosine-dependent regulation of messenger RNA stability. *Nature* 505:117–20
115. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, et al. 2015. *N*⁶-methyladenosine modulates messenger RNA translation efficiency. *Cell* 161:1388–99
116. Shi H, Wang X, Lu Z, Zhao BS, Ma H, et al. 2017. YTHDF3 facilitates translation and decay of *N*⁶-methyladenosine-modified RNA. *Cell Res.* 27:315–28
117. Lasman L, Krupalnik V, Viukov S, Mor N, Aguilera-Castrejon A, et al. 2020. Context-dependent functional compensation between Ythdf m⁶A reader proteins. *Genes Dev.* 34:1373–91
118. Kontur C, Jeong M, Cifuentes D, Giraldez AJ. 2020. Ythdf m⁶A readers function redundantly during zebrafish development. *Cell Rep.* 33:108598
119. Flamand MN, Ke K, Tamming R, Meyer KD. 2022. Single-molecule identification of the target RNAs of different RNA binding proteins simultaneously in cells. *Genes Dev.* 36:1002–15
120. Sommer S, Lavi U, Darnell JE Jr. 1978. The absolute frequency of labeled *N*-6-methyladenosine in HeLa cell messenger RNA decreases with label time. *J. Mol. Biol.* 124:487–99
121. Batista PJ, Molinie B, Wang J, Qu K, Zhang J, et al. 2014. m⁶A RNA modification controls cell fate transition in mammalian embryonic stem cells. *Cell Stem Cell* 15:707–19
122. Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, et al. 2015. m⁶A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. *Science* 347:1002–6
123. Du H, Zhao Y, He J, Zhang Y, Xi H, et al. 2016. YTHDF2 destabilizes m⁶A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. *Nat. Commun.* 7:12626
124. Flamand MN, Meyer KD. 2022. m⁶A and YTHDF proteins contribute to the localization of select neuronal mRNAs. *Nucleic Acids Res.* 50:4464–83
125. Park OH, Ha H, Lee Y, Boo SH, Kwon DH, et al. 2019. Endoribonucleolytic cleavage of m⁶A-containing RNAs by RNase P/MRP complex. *Mol. Cell* 74:494–507.e8
126. Boo SH, Ha H, Lee Y, Shin MK, Lee S, Kim YK. 2022. UPF1 promotes rapid degradation of m⁶A-containing RNAs. *Cell Rep.* 39:110861
127. Lin X, Chai G, Wu Y, Li J, Chen F, et al. 2019. RNA m⁶A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. *Nat. Commun.* 10:2065
128. Meyer KD. 2019. m⁶A-mediated translation regulation. *Biochim. Biophys. Acta Gene Regul. Mech.* 1862:301–9
129. Shi H, Zhang X, Weng YL, Lu Z, Liu Y, et al. 2018. m⁶A facilitates hippocampus-dependent learning and memory through YTHDF1. *Nature* 563:249–53

130. Merkurjev D, Hong WT, Iida K, Oomoto I, Goldie BJ, et al. 2018. Synaptic N^6 -methyladenosine (m^6A) epitranscriptome reveals functional partitioning of localized transcripts. *Nat. Neurosci.* 21:1004–14
131. Weng YL, Wang X, An R, Cassin J, Vissers C, et al. 2018. Epitranscriptomic m^6A regulation of axon regeneration in the adult mammalian nervous system. *Neuron* 97:313–25.e6
132. Li A, Chen YS, Ping XL, Yang X, Xiao W, et al. 2017. Cytoplasmic m^6A reader YTHDF3 promotes mRNA translation. *Cell Res.* 27:444–47
133. Flamand MN, Meyer KD. 2019. The epitranscriptome and synaptic plasticity. *Curr. Opin. Neurobiol.* 59:41–48
134. Yoon KJ, Ringeling FR, Vissers C, Jacob F, Pokrass M, et al. 2017. Temporal control of mammalian cortical neurogenesis by m^6A methylation. *Cell* 171:877–89.e17
135. Zhuang M, Li X, Zhu J, Zhang J, Niu F, et al. 2019. The m^6A reader YTHDF1 regulates axon guidance through translational control of Robo3.1 expression. *Nucleic Acids Res.* 47:4765–77
136. Zhang Z, Wang M, Xie D, Huang Z, Zhang L, et al. 2018. METTL3-mediated N^6 -methyladenosine mRNA modification enhances long-term memory consolidation. *Cell Res.* 28:1050–61
137. Koranda JL, Dore L, Shi H, Patel MJ, Vaasjo LO, et al. 2018. Mettl14 is essential for epitranscriptomic regulation of striatal function and learning. *Neuron* 99:283–92.e5
138. Zong X, Xiao X, Shen B, Jiang Q, Wang H, et al. 2021. The N^6 -methyladenosine RNA-binding protein YTHDF1 modulates the translation of *TRAF6* to mediate the intestinal immune response. *Nucleic Acids Res.* 49:5537–52
139. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. 2015. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. *Nucleic Acids Res.* 43:D512–20
140. Fei Q, Zou Z, Roundtree IA, Sun HL, He C. 2020. YTHDF2 promotes mitotic entry and is regulated by cell cycle mediators. *PLoS Biol.* 18:e3000664
141. Hou G, Zhao X, Li L, Yang Q, Liu X, et al. 2021. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m^6A -modified mRNAs. *Nucleic Acids Res.* 49:2859–77
142. Edupuganti RR, Geiger S, Lindeboom RGH, Shi H, Hsu PJ, et al. 2017. N^6 -methyladenosine (m^6A) recruits and repels proteins to regulate mRNA homeostasis. *Nat. Struct. Mol. Biol.* 24:870–78
143. Arguello AE, DeLiberto AN, Kleiner RE. 2017. RNA chemical proteomics reveals the N^6 -methyladenosine (m^6A)-regulated protein–RNA interactome. *J. Am. Chem. Soc.* 139:17249–52
144. Huang H, Weng H, Sun W, Qin X, Shi H, et al. 2018. Recognition of RNA N^6 -methyladenosine by IGF2BP proteins enhances mRNA stability and translation. *Nat. Cell Biol.* 20:285–95
145. Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, et al. 2015. 5' UTR m^6A promotes cap-independent translation. *Cell* 163:999–1010
146. Yang Y, Fan X, Mao M, Song X, Wu P, et al. 2017. Extensive translation of circular RNAs driven by N^6 -methyladenosine. *Cell Res.* 27:626–41
147. Sun L, Fazal FM, Li P, Broughton JP, Lee B, et al. 2019. RNA structure maps across mammalian cellular compartments. *Nat. Struct. Mol. Biol.* 26:322–30
148. Zhang F, Kang Y, Wang M, Li Y, Xu T, et al. 2018. Fragile X mental retardation protein modulates the stability of its m^6A -marked messenger RNA targets. *Hum. Mol. Genet.* 27:3936–50
149. Edens BM, Vissers C, Su J, Arumugam S, Xu Z, et al. 2019. FMRP modulates neural differentiation through m^6A -dependent mRNA nuclear export. *Cell Rep.* 28:845–54.e5
150. Hsu PJ, Shi H, Zhu AC, Lu Z, Miller N, et al. 2019. The RNA-binding protein FMRP facilitates the nuclear export of N^6 -methyladenosine-containing mRNAs. *J. Biol. Chem.* 294:19889–95
151. Wu R, Li A, Sun B, Sun JG, Zhang J, et al. 2019. A novel m^6A reader Prrc2a controls oligodendroglial specification and myelination. *Cell Res.* 29:23–41
152. Choi SH, Flamand MN, Liu B, Zhu H, Hu M, et al. 2022. RBM45 is an m^6A -binding protein that affects neuronal differentiation and the splicing of a subset of mRNAs. *Cell Rep.* 40:111293
153. Roost C, Lynch SR, Batista PJ, Qu K, Chang HY, Kool ET. 2015. Structure and thermodynamics of N^6 -methyladenosine in RNA: a spring-loaded base modification. *J. Am. Chem. Soc.* 137:2107–15
154. Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. 2015. N^6 -methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. *Nature* 518:560–64

155. Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L, Pan T. 2017. *N*⁶-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. *Nucleic Acids Res.* 45:6051–63
156. Wu B, Su S, Patil DP, Liu H, Gan J, et al. 2018. Molecular basis for the specific and multivalent recognitions of RNA substrates by human hnRNP A2/B1. *Nat. Commun.* 9:420
157. Wang Y, Li Y, Toth JJ, Petroski MD, Zhang Z, Zhao JC. 2014. *N*⁶-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. *Nat. Cell Biol.* 16:191–98
158. Boo SH, Ha H, Kim YK. 2022. m¹A and m⁶A modifications function cooperatively to facilitate rapid mRNA degradation. *Cell Rep.* 40:111317
159. Yang Y, Wang L, Han X, Yang WL, Zhang M, et al. 2019. RNA 5-methylcytosine facilitates the maternal-to-zygotic transition by preventing maternal mRNA decay. *Mol. Cell* 75:1188–202.e11
160. Chen H, Yang H, Zhu X, Yadav T, Ouyang J, et al. 2020. m⁵C modification of mRNA serves a DNA damage code to promote homologous recombination. *Nat. Commun.* 11:2834
161. Levi O, Arava YS. 2021. Pseudouridine-mediated translation control of mRNA by methionine aminoacyl tRNA synthetase. *Nucleic Acids Res.* 49:432–43
162. Xiang Y, Zhou C, Zeng Y, Guo Q, Huang J, et al. 2021. NAT10-mediated N⁴-acetylcytidine of RNA contributes to post-transcriptional regulation of mouse oocyte maturation in vitro. *Front. Cell Dev. Biol.* 9:704341
163. Fedeles BI, Singh V, Delaney JC, Li D, Essigmann JM. 2015. The AlkB family of Fe(II)/ α -ketoglutarate-dependent dioxygenases: repairing nucleic acid alkylation damage and beyond. *J. Biol. Chem.* 290:20734–42
164. Hess ME, Hess S, Meyer KD, Verhagen LA, Koch L, et al. 2013. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. *Nat. Neurosci.* 16:1042–48
165. Fu Y, Jia G, Pang X, Wang RN, Wang X, et al. 2013. FTO-mediated formation of *N*⁶-hydroxymethyladenosine and *N*⁶-formyladenosine in mammalian RNA. *Nat. Commun.* 4:1798
166. Zou S, Toh JD, Wong KH, Gao YG, Hong W, Woon EC. 2016. *N*⁶-methyladenosine: a conformational marker that regulates the substrate specificity of human demethylases FTO and ALKBH5. *Sci. Rep.* 6:25677
167. Zhang X, Wei LH, Wang Y, Xiao Y, Liu J, et al. 2019. Structural insights into FTO's catalytic mechanism for the demethylation of multiple RNA substrates. *PNAS* 116:2919–24
168. Koh CWQ, Goh YT, Goh WSS. 2019. Atlas of quantitative single-base-resolution *N*⁶-methyl-adenine methylomes. *Nat. Commun.* 10:5636
169. Jia G, Yang CG, Yang S, Jian X, Yi C, et al. 2008. Oxidative demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA by mouse and human FTO. *FEBS Lett.* 582:3313–19
170. Wei J, Liu F, Lu Z, Fei Q, Ai Y, et al. 2018. Differential m⁶A, m⁶A_m, and m¹A demethylation mediated by FTO in the cell nucleus and cytoplasm. *Mol. Cell* 71:973–85.e5
171. Gulati P, Cheung MK, Antrobus R, Church CD, Harding HP, et al. 2013. Role for the obesity-related FTO gene in the cellular sensing of amino acids. *PNAS* 110:2557–62
172. Yu J, Chen M, Huang H, Zhu J, Song H, et al. 2018. Dynamic m⁶A modification regulates local translation of mRNA in axons. *Nucleic Acids Res.* 46:1412–23
173. Vujovic P, Stamenkovic S, Jasic N, Latic I, Djurasevic SF, et al. 2013. Fasting induced cytoplasmic Fto expression in some neurons of rat hypothalamus. *PLoS ONE* 8:e63694
174. Walters BJ, Mercaldo V, Gillon CJ, Yip M, Neve RL, et al. 2017. The role of the RNA demethylase FTO (fat mass and obesity-associated) and mRNA methylation in hippocampal memory formation. *Neuropsychopharmacology* 42:1502–10
175. Zhu T, Yong XLH, Xia D, Widagdo J, Anggono V. 2018. Ubiquitination regulates the proteasomal degradation and nuclear translocation of the fat mass and obesity-associated (FTO) protein. *J. Mol. Biol.* 430:363–71
176. Mauer J, Sindelar M, Despic V, Guez T, Hawley BR, et al. 2019. FTO controls reversible m⁶Am RNA methylation during snRNA biogenesis. *Nat. Chem. Biol.* 15:340–47
177. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, et al. 2014. FTO-dependent demethylation of *N*⁶-methyladenosine regulates mRNA splicing and is required for adipogenesis. *Cell Res.* 24:1403–19
178. Wei J, Yu X, Yang L, Liu X, Gao B, et al. 2022. FTO mediates LINE1 m⁶A demethylation and chromatin regulation in mESCs and mouse development. *Science* 376:968–73

179. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, et al. 2007. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* 316:889–94
180. Lan N, Lu Y, Zhang Y, Pu S, Xi H, et al. 2020. FTO – a common genetic basis for obesity and cancer. *Front. Genet.* 11:559138
181. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, et al. 2014. Obesity-associated variants within FTO form long-range functional connections with IRX3. *Nature* 507:371–75
182. Reitz C, Tosto G, Mayeux R, Luchsinger JA, NIA-LOAD/NCRAD Family Study Group, Alzheimer's Disease Neuroimaging I. 2012. Genetic variants in the fat and obesity associated (FTO) gene and risk of Alzheimer's disease. *PLOS ONE* 7:e50354
183. Keller L, Xu W, Wang HX, Winblad B, Fratiglioni L, Graff C. 2011. The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer's disease risk: a prospective cohort study. *J. Alzheimers Dis.* 23:461–69
184. Chang R, Huang Z, Zhao S, Zou J, Li Y, Tan S. 2022. Emerging roles of FTO in neuropsychiatric disorders. *Biomed. Res. Int.* 2022:2677312
185. Li Y, Su R, Deng X, Chen Y, Chen J. 2022. FTO in cancer: functions, molecular mechanisms, and therapeutic implications. *Trends Cancer* 8:598–614
186. Li Z, Weng H, Su R, Weng X, Zuo Z, et al. 2017. FTO plays an oncogenic role in acute myeloid leukemia as a N^6 -methyladenosine RNA demethylase. *Cancer Cell* 31:127–41
187. Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, et al. 2018. R-2HG exhibits anti-tumor activity by targeting FTO/ m^6A /MYC/CEBPA signaling. *Cell* 172:90–105.e23
188. Cui Q, Shi H, Ye P, Li L, Qu Q, et al. 2017. m^6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. *Cell Rep.* 18:2622–34
189. Bodi Z, Zhong S, Mehra S, Song J, Graham N, et al. 2012. Adenosine methylation in arabidopsis mRNA is associated with the 3' end and reduced levels cause developmental defects. *Front. Plant Sci.* 3:48
190. Yu Q, Liu S, Yu L, Xiao Y, Zhang S, et al. 2021. RNA demethylation increases the yield and biomass of rice and potato plants in field trials. *Nat. Biotechnol.* 39:1581–88
191. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, et al. 2013. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Mol. Cell* 49:18–29
192. Aik W, Scotti JS, Choi H, Gong L, Demetriades M, et al. 2014. Structure of human RNA N^6 -methyladenine demethylase ALKBH5 provides insights into its mechanisms of nucleic acid recognition and demethylation. *Nucleic Acids Res.* 42:4741–54
193. Feng C, Liu Y, Wang G, Deng Z, Zhang Q, et al. 2014. Crystal structures of the human RNA demethylase Alkbh5 reveal basis for substrate recognition. *J. Biol. Chem.* 289:11571–83
194. Xu C, Liu K, Tempel W, Demetriades M, Aik W, et al. 2014. Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single-stranded N^6 -methyladenosine RNA demethylation. *J. Biol. Chem.* 289:17299–311
195. Li Z, Wang P, Li J, Xie Z, Cen S, et al. 2021. The N^6 -methyladenosine demethylase ALKBH5 negatively regulates the osteogenic differentiation of mesenchymal stem cells through PRMT6. *Cell Death Dis.* 12:578
196. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, et al. 2016. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m^6A -demethylation of NANOG mRNA. *PNAS* 113:E2047–56
197. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, et al. 2017. m^6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. *Cancer Cell* 31:591–606.e6
198. Liu F, Clark W, Luo G, Wang X, Fu Y, et al. 2016. ALKBH1-mediated tRNA demethylation regulates translation. *Cell* 167:1897
199. Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, et al. 2017. AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. *Sci. Rep.* 7:42271
200. Zhang C, Jia G. 2018. Reversible RNA modification N^1 -methyladenosine (m^1A) in mRNA and tRNA. *Genom. Proteom. Bioinform.* 16:155–61

201. Kohli RM, Zhang Y. 2013. TET enzymes, TDG and the dynamics of DNA demethylation. *Nature* 502:472–79
202. Fu L, Guerrero CR, Zhong N, Amato NJ, Liu Y, et al. 2014. Tet-mediated formation of 5-hydroxymethylcytosine in RNA. *J. Am. Chem. Soc.* 136:11582–85
203. Delatte B, Wang F, Ngoc LV, Collignon E, Bonvin E, et al. 2016. Transcriptome-wide distribution and function of RNA hydroxymethylcytosine. *Science* 351:282–85
204. Huber SM, van Delft P, Mendil L, Bachman M, Smollett K, et al. 2015. Formation and abundance of 5-hydroxymethylcytosine in RNA. *ChemBiochemistry* 16:752–55
205. Lan J, Rajan N, Bizet M, Penning A, Singh NK, et al. 2020. Functional role of Tet-mediated RNA hydroxymethylcytosine in mouse ES cells and during differentiation. *Nat. Commun.* 11:4956